{"analyses":[{"ciLowerLimit":"0.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.88","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","otherAnalysisDescription":"The hazard ratio was estimated from a stratified Cox regression model stratified by rituximab-refractory status, number of prior lines of therapy and geographic region.","pValue":"0.0177","paramType":"Hazard Ratio (HR)","paramValue":"0.44","statisticalComment":"The p-value was stratified by rituximab-refractory status, number of prior lines of therapy and geographic region.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"26.8","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"31.4","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause. Median OS was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Obinutuzumab 1000 milligrams (mg) intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6; and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG000","title":"Obinutuzumab"},{"description":"Zanubrutinib 160 mg twice a day orally with or without food and obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, Day 1 of Cycles 2 to 6, and then every 8 weeks for an additional 24 months or until disease progression. Each treatment cycle was 28 days.","id":"OG001","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"MEDIAN","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"From first dose to primary analysis data cutoff (08OCT2021) start of a new anticancer therapy, or the crossover date, whichever came first. Median follow-up was 12.45 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}